EBOS Group Reports Lapse of 7,878 Performance Rights

EBOS Group Limited ( (AU:EBO) ) has shared an announcement.

EBOS Group Limited has notified the market that 7,878 performance rights, trading under the ASX code EBOAA, have lapsed. The securities ceased because the conditions attached to these performance rights were not met or became incapable of being satisfied as of 24 April 2026, resulting in a small reduction in the company’s pool of potential equity-based incentives for participants.

The lapse of these performance rights slightly reduces potential future dilution for existing shareholders, while signaling that specific performance or vesting hurdles were not achieved. Although the volume is modest relative to EBOS’s overall capital structure, the move clarifies the status of these conditional securities and tidies up the company’s issued capital register.

The most recent analyst rating on (AU:EBO) stock is a Buy with a A$22.92 price target. To see the full list of analyst forecasts on EBOS Group Limited stock, see the AU:EBO Stock Forecast page.

More about EBOS Group Limited

EBOS Group Limited is an Australasian company listed on the ASX under the code EBO. It operates in the healthcare and animal care sectors, supplying pharmaceuticals, medical products and related services across Australia and New Zealand, with a focus on wholesale distribution and related healthcare solutions.

Average Trading Volume: 155,758

Technical Sentiment Signal: Sell

Current Market Cap: A$3.65B

For a thorough assessment of EBO stock, go to TipRanks’ Stock Analysis page.